(281) 713-2962
800 Rockmead Drive, Suite 155
Kingwood, TX 77339
[email protected]
Registry of the Natural History of Recurrent Pericarditis in Pediatric and Adult Patients
Status: Recruiting
Location: Alaska Heart & Vascular Institute, Allegheny General Hospital, Barnes-Jewish Hospital/Washington University, Cincinnati Children's Hospital Medical Center, Houston Methodist Hospital, Johns Hopkins University, Legacy Hospital and Health Center DBA Legacy Research Institute, Midwest Cardiovascular Research Foundation, NYU Langone Health, Northwell Health - Lenox Hill Hospital, Pima Heart and Vascular, Scripps Health, Seattle Children's Hospital, TKL Research Inc., University of California San Diego, University of Nebraska Medical Center, University of Vermont Medical Center, Virginia Commonwealth University
Conditions: Alaska Heart & Vascular Institute, Allegheny General Hospital, Barnes-Jewish Hospital/Washington University, Cincinnati Children's Hospital Medical Center, Houston Methodist Hospital, Johns Hopkins University, Legacy Hospital and Health Center DBA Legacy Research Institute, Midwest Cardiovascular Research Foundation, NYU Langone Health, Northwell Health - Lenox Hill Hospital, Pima Heart and Vascular, Scripps Health, Seattle Children's Hospital, TKL Research Inc., University of California San Diego, University of Nebraska Medical Center, University of Vermont Medical Center, Virginia Commonwealth University
City/State:
Anchorage, Alaska
Tucson, Arizona
La Jolla, California
San Diego, California
Davenport, Iowa
Baltimore, Maryland
Boston, Massachusetts
Minneapolis, Minnesota
Rochester, Minnesota
Saint Louis, Missouri
Omaha, Nebraska
Fair Lawn, New Jersey
New York, New York
New York, New York
Cincinnati, Ohio
Cleveland, Ohio
Portland, Oregon
Pittsburgh, Pennsylvania
Houston, Texas
Burlington, Vermont
Richmond, Virginia
Seattle, Washington
Contact Information:
Amanda Chriswell 907-550-2247 [email protected]
Aleksander Herber 520-576-4133 [email protected]
Study Coordinator 858-246-2413
Chelsea Butler 858-824-5241 [email protected]
Lori Christensen 563-324-2828 [email protected]
Kondal Reddy 410-502-2945 [email protected]
Wesley Xiong 617-732-4719 [email protected]
Stephanie Ebnet 612-863-3833
Halley Davidson 507-422-6246 [email protected]
Karen Bult 314-286-1767 [email protected]
Nathan Muhn 402-836-9364 natha[email protected]
Uzoma Okamgba-Nwoke 201-587-0500 ext 2548 [email protected]
Alexander Auchus 212-263-0855 [email protected]
212-434-4174 [email protected]
Mary Banks 513-636-2147 [email protected]
216-445-9007 [email protected]
503-413-1612 [email protected]
Geetha Rayarao 412-359-4076
Eilidh Cowan 346-238-4552 [email protected]
Alexandria Loutrel 802-847-8913 [email protected]
Emily Federmann 804-828-2775 [email protected]
Nair Deepthi 206-987-1014 [email protected]
The registry will focus on furthering the understanding of the natural history of recurrent pericarditis (RP), as well as document RP-related clinical, health-related quality of life (HRQoL), and economic burden and will assist the medical community to refine or develop data-driven recommendations for clinical management of RP patients to optimize clinical outcomes. It also aims to generate data in support of the impact of rilonacept on clinical outcomes in a real-world population.
Read moreImpact of CardiolRx on Recurrent Pericarditis
Status: Not yet recruiting
Location:
Conditions:
City/State:
Rochester, Minnesota
Cleveland, Ohio
Contact Information:
S. A. Luis, MD [email protected]
Sonya Mihalus, BSN [email protected]
Patients with recurrent pericarditis who are refractory or intolerant to current therapeutic management options or who require long-term administration of corticosteroids to control their disease are particularly challenging to manage. The pathogenesis of pericarditis involves the activation of the inflammasome. CardiolRxTM (a pure cannabidiol [CBD] solution) is known to have anti-inflammatory properties, including modulation of inflammasome signaling. This pilot study is to assess the tolerance and safety of CardiolRxTM during the resolution of pericarditis symptoms, assess improvement in objective measures of disease, and during the extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids while taking CardiolRxTM.
Read moreEffcacy and Safety of RPH-104 Treatment in Patients with Recurrent Pericarditis
Status: Not yet recruiting
Location: Virginia Commonwealth University
Conditions: Virginia Commonwealth University
City/State:
Richmond, Virginia
Contact Information:
Antonio Abbate, MD 804-828-0513 [email protected]
“The primary purpose of this study is the evaluation of the efficacy and safety of RPH-104 treatment in patients with recurrent pericarditis.
Pharmacokinetic and pharmacodynamic parameters of RPH-104 multiple doses in this patient population will be assessed as well.”
Myocardial Injury and Dysfunction Associated with COVID-19 Vaccination
Status: Recruiting
Location: University of Colorado Anschutz Medical Campus
Conditions: University of Colorado Anschutz Medical Campus
City/State:
Aurora, Colorado
Contact Information:
Rachel Rosenberg, MS 303-724-4544 [email protected]
Natasha Altman, MD 303-724-4544 [email protected]
The overall goal of the study is to investigate the characteristics and potential mechanisms responsible for myocardial injury and dysfunction in patients after COVID-19 vaccination. Cardiac damage will be assessed with cardiac MRI and endomyocardial biopsy (EmBx) histopathology. Myocardial gene expression will be measured in RNA extracted from EmBxs mRNA abundance compared to nonfailing and failing control hearts.
Read moreMayo AVC Registry and Biobank
Status: Recruiting
Location: Mayo Clinic
Conditions: Mayo Clinic
City/State:
Rochester, Minnesota
Contact Information:
Nicholas Wozniak 507-255-8794 [email protected]
Shahid Karim, MD 507-422-0766 [email protected]
“Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death.
The Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history of AVC or sudden cardiac death which may be due to AVC, from the US and UK. Family members who are blood-relatives will also be invited, including those who do not have the condition. Data collected include symptoms, ECG, echocardiographic, MRI, Holter, loop recorder, biopsies, exercise stress testing, blood, buccal and saliva samples.
Objectives of the study:
Discover new genes or altered genes (variants) which cause AVC
Identify biomarkers which predict (2a) disease onset, (2b) disease progression, (2c) and the likelihood of arrhythmia (ventricular, supra-ventricular and atrial fibrillation)
Correlate genotype with phenotype in confirmed cases of AVC followed longitudinally using clinical, electrocardiographic and imaging data.
Characterize desmosomal changes in buccal mucosal cells with genotype and validate with gold-standard endomyocardial biopsies”
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Status: Recruiting
Location: "Beth Israel Deaconess Medical Center ", Allegheny-Singer Research Institution, Boston Medical Center, Brigham and Women's Hospital, Cedars-Sinai Medical Center, Lehigh Valley Health Network, Memorial Sloan Kettering Cancer Center, University of California Los Angeles, University of Kansas Medical Center, University of Kentucky, University of Michigan, University of North Carolina Chapel Hill, University of Texas Southwestern, University of Utah
Conditions: "Beth Israel Deaconess Medical Center ", Allegheny-Singer Research Institution, Boston Medical Center, Brigham and Women's Hospital, Cedars-Sinai Medical Center, Lehigh Valley Health Network, Memorial Sloan Kettering Cancer Center, University of California Los Angeles, University of Kansas Medical Center, University of Kentucky, University of Michigan, University of North Carolina Chapel Hill, University of Texas Southwestern, University of Utah
City/State:
Los Angeles, California
Los Angeles, California
Kansas City, Kansas
Lexington, Kentucky
Boston, Massachusetts
Ann Arbor, Michigan
New York, New York
Chapel Hill, North Carolina
Bethlehem, Pennsylvania
Pittsburgh, Pennsylvania
Dallas, Texas
Houston, Texas
Salt Lake City, Utah
Contact Information:
Kiranbir Josan, MD
Eric Yang, MD
Charles Porter, MD
Amit Arbune, MD
Daniel Zlotoff, MD, PhD 617-726-2000 [email protected]
Aarti Asnani or Abul Aritizia, MD
Omar Siddiqi
Anju Nohria, MD [email protected]
Salim Hayek, MD [email protected]
Dipti Gupta, MD
Brian Jensen, MD
Nicholas Trask
Valentyna Ivanova
Saketh Nadimpalli [email protected]
Nicolas Palaskas [email protected]
Anees Daud, MD
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
Read moreMYTHS – MYocarditis THerapy with Steroids
Status: Not yet recruiting
Location: University of California San Diego, Virginia Commonwealth University
Conditions: University of California San Diego, Virginia Commonwealth University
City/State:
San Diego, California
Richmond, Virginia
Contact Information:
Eric D Adler, MD
Antonio Abbate, MD
This is a phase III, multi-center international, single blind randomized controlled trial to test the efficacy of pulsed intravenous (IV) methylprednisolone versus standard therapy on top of maximal support in patients with Acute myocarditis (AM).
Read moreImpact of CardiolRx on Myocardial Recovery in Acute Myocarditis
Status: Recruiting
Location: Massachusetts General Hospital, McGill University Health Care, MedStar Heart and Vascular Institute, Minneapolis Heart Institute Foundation, Palm Springs Community Health Centre, University of Alberta Hospital, University of Pennsylvania, University of Pittsburgh Medical Center, Virginia Commonwealth University
Conditions: Massachusetts General Hospital, McGill University Health Care, MedStar Heart and Vascular Institute, Minneapolis Heart Institute Foundation, Palm Springs Community Health Centre, University of Alberta Hospital, University of Pennsylvania, University of Pittsburgh Medical Center, Virginia Commonwealth University
City/State:
Washington, DC
Miami Lakes, Florida
Boston, Massachusetts
Minneapolis, Minnesota
Cleveland, Ohio
Malvern, Pennsylvania
Pittsburgh, Pennsylvania
Richmond, Virginia
Edmonton, Alberta, Canada
Montreal, Quebec, Canada
Contact Information:
Dr. Mark Hofmeyer [email protected]
Dr. Yanely Pineiro
Dr. Daniel Zlotoff [email protected]
Dr. David Lin [email protected]
Dr. Pavan Bhat [email protected]
Dr. Victor Ferrari [email protected]
Dr. Jessica Huston [email protected]
Dr. Roshanak Markley [email protected]
Dr. Justin Ezekowitz [email protected]
Dr. Matthias Friedrich [email protected]
“Multi-center, double-blind, placebo-controlled, parallel group design. Patients with myocarditis within 90 days of onset of symptoms will be screened and, if eligible, randomized to CardiolRx or placebo.
CardiolRx is pharmaceutically produced Cannabidiol and is free of tetrahydrocannabinol (THC<5 ppm). The treatment period is 12 weeks; a last follow-up visit is scheduled one week after the last treatment, 13 weeks after randomization. Study assessments include Cardiac Magnetic Resonance imaging (CMR), ECG monitoring, 24-hour Holter assessments, the Kansas City Cardiomyopathy Questionnaire (KCCQ), the Columbia-Suicide Severity Rating Scale (C-SSRS) as well as physical exams and laboratory tests.
The primary outcome parameters are measured by CMR. Secondary outcomes include clinical endpoints and changes in inflammatory and biomarkers."
Global Cardio Oncology Registry
Status: Recruiting
Location: Florida
Conditions: Florida
City/State:
Weston, Florida
Contact Information:
"Diego Sadler, MD FACC 561-389-8833 [email protected] "
Rohit Moudgil, MD PhD 216-445-1932 [email protected]
G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.
Read moreCell Free DNA in Cardiac Sarcoidosis
Status: Recruiting
Location: University of Iowa
Conditions: University of Iowa
City/State:
Iowa City, Iowa
Contact Information:
Brenda Werner, RN 319-353-8862 [email protected]
Nabeel Hamzeh, MD 319-356-8343 [email protected]
“Sarcoidosis is a multisystem granulomatous disease of unknown cause that can affect any organ in the body, including the heart. Granulomatous myocarditis can lead to ventricular dysfunction and ventricular arrhythmias causing significant morbidity and mortality. Immunosuppressive therapy (IST) has been shown to reverse active myocarditis and preserve left ventricular (LV) function and in some cases improve LV function. In addition, IST can suppress arrhythmias that develop due to active myocarditis and prevent the formation of scar.
The potential role of cardiac biomarkers, including brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), and cardiac troponins, in detecting active myocarditis is limited and studies have been disappointing. At present, there are no biomarkers to detect active myocarditis and the use of advanced imaging modalities (FDG-PET) for assessing and monitoring active myocarditis is not feasible or practical and is associate with high radiation exposure. As such, a biomarker that is reflective of active myocarditis and that is cardiac specific will assist physicians in assessing the presence of active myocarditis to guide therapeutic decisions and to assess response to therapy which can limit further cardiac damage.
Cell free DNA (cfDNA) are fragments of genomic DNA that are released into the circulation from dying or damaged cells. It is a powerful diagnostic tool in cancer, transplant rejection and fetal medicine especially when the genomic source differs from the host. A novel technique that relies on tissue unique CpG methylation patterns can identify the tissue source of cell free DNA in an individual reflecting potential tissue injury. We will be conducting a pilot study to explore the utility of this diagnostic tool to identify granulomatous myocarditis in patients with sarcoidosis.”